



10/550624

[Fig. 1]




10/550624

[Fig. 2]




10/550624

[Fig. 3]




10/15 50624

[Fig. 4]



10/15 50624

[Fig. 5]




Lanes 1-7: Strains prepared in Example 1

Lane 8: NIHONBARE (Non-Transformant)

Lane 9 A strain prepared in Example 1


10/15 50621

[Fig. 6]




pGlbGLP-Hm

[Fig. 7]




10/550624

[Fig. 8]




[Fig. 9]




10/550624


[Fig. 10]




[Fig. 11]



[Fig. 12]




[Fig. 13]




10/550624

[Fig. 14]



10/550624

[Fig. 15]



native : GLP-1(7-36amide)

34N : [Ser8,Gln26,Asn34]-GLP-1(7-36)

34D : [Ser8,Gln26,Asp34]-GLP-1(7-36)

5 : 5 μg/kg Subcutaneous administration

20 : 20 μg/kg Subcutaneous administration